MD HB1469

Maryland Insurance Administration must convene a workgroup to study the current "specialty drug" definition under § 15–847 of the Insurance Article

Workgroup membership includes representatives from pharmacy benefits managers, independent pharmacists, carriers (both those that own and do not own PBMs), managed care organizations, hospitals, and other health care providers

Study must assess which stakeholders benefit or are disadvantaged by the current definition, its impact on patients, and any unintended consequences

Workgroup must compare Maryland's definition to federal, other states', and international definitions of "specialty drug" and recommend a new definition in the best interest of patients and stakeholders

Report due to the Governor and General Assembly by January 1, 2027; the Act takes effect July 1, 2026 and automatically sunsets on June 30, 2027